{"product_id":"markers-in-cardiology-9781405134187","title":"Markers in Cardiology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWith the rapid development of the field of cardiac biomarkers comes a need for updated guidance on how to use them clinically. Drs. Adams, Jaffe, and Apple meet that need with this timely reference.    Taking a case-oriented approach for the greatest clinical relevance, the book bridges the gap between science and practice.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"I think this is a good book and good value for money. It is fairly light reading and I found myself wanting to make notes and use it as a point of reference as it pulls things together well. Therefore, I would recommend it to others.\" (\u003ci\u003eCardiology News\u003c\/i\u003e, February 2009)\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eContents. \u003cp\u003eContributors.\u003c\/p\u003e \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Cardiac troponins\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e1 Basics of cardiac troponin: practical aspects of assays, potential.\u003c\/p\u003e \u003cp\u003eanalytical confounders, and clinical interpretation.\u003c\/p\u003e \u003cp\u003eFred S. Apple (University of Minnesota School of Medicine).\u003c\/p\u003e \u003cp\u003e2 Diagnostic use of cardiac troponins in ST-segment elevation.\u003c\/p\u003e \u003cp\u003emyocardial infarction.\u003c\/p\u003e \u003cp\u003eSusanne Korff (Medizinische Universitätsklinik Heidelberg), Hugo A. Katus (Department of Cardiology), Evangelos Giannitsis (Department of Cardiology).\u003c\/p\u003e \u003cp\u003e3 Therapeutic implications of cardiac troponins in ST-segment.\u003c\/p\u003e \u003cp\u003eelevation and non-ST-segment elevation myocardial.\u003c\/p\u003e \u003cp\u003einfarction.\u003c\/p\u003e \u003cp\u003eTracy Y. Wang, John M. Castor, L. Kristin Newby.\u003c\/p\u003e \u003cp\u003e4 Ischemic heart disease in the absence of overt coronary.\u003c\/p\u003e \u003cp\u003eartery disease.\u003c\/p\u003e \u003cp\u003eAllan S. Jaffe (Mayo Clinic).\u003c\/p\u003e \u003cp\u003e5 So you think you have a “false positive’’ troponin?.\u003c\/p\u003e \u003cp\u003eJesse E. Adams (Jewish Hospital Heart and Lung Institute).\u003c\/p\u003e \u003cp\u003e6 Use of cardiac troponin in patients in non-ischemic pathologies.\u003c\/p\u003e \u003cp\u003eand exposure to environmental toxins.\u003c\/p\u003e \u003cp\u003eFred S. Apple (University of Minnesota School of Medicine).\u003c\/p\u003e \u003cp\u003e7 Cardiac troponins in patients with congestive heart failure.\u003c\/p\u003e \u003cp\u003eJesse Adams (Jewish Hospital Heart and Lung Institute).\u003c\/p\u003e \u003cp\u003e8 Troponins and the critically Ill patient.\u003c\/p\u003e \u003cp\u003eJose Antonio Perez (Mayo Clinic \u0026amp; Medical School), Luciano Babuin (Cardiovascular Division \u0026amp; Cardiovascular), Allan S. Jaffe (Mayo Clinic).\u003c\/p\u003e \u003cp\u003e9 Cardiac troponins and renal failure.\u003c\/p\u003e \u003cp\u003eSuresh Pothuru (University of Maryland), Christopher deFilippi (University of Maryland).\u003c\/p\u003e \u003cp\u003e10 Cardiac biomarkers: detection of in-hospital myocardial.\u003c\/p\u003e \u003cp\u003ereinfarction.\u003c\/p\u003e \u003cp\u003eFred S. Apple (University of Minnesota School of Medicine).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Natriuretic peptides\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e11 The future: interpreting new guidelines for myocardial.\u003c\/p\u003e \u003cp\u003einfarction.\u003c\/p\u003e \u003cp\u003eAllan S. Jaffe (Mayo Clinic).\u003c\/p\u003e \u003cp\u003e12 Basics of natriuretic peptides: practical aspects of assays,.\u003c\/p\u003e \u003cp\u003epotential analytical confounders, and clinical interpretation.\u003c\/p\u003e \u003cp\u003eAlan H.B. Wu (San Francisco General Hospital).\u003c\/p\u003e \u003cp\u003e13 Natriruetic peptides in clinical practice.\u003c\/p\u003e \u003cp\u003eAlan Maisel (University of California).\u003c\/p\u003e \u003cp\u003e14 Outpatient evaluation for cardiovascular diseases using.\u003c\/p\u003e \u003cp\u003enatriuretic peptide testing.\u003c\/p\u003e \u003cp\u003eAaron L. Baggish (Massachusetts General Hospital), James L. Januzzi (Harvard Medical School).\u003c\/p\u003e \u003cp\u003e15 Natriuretic peptides in patients with renal failure.\u003c\/p\u003e \u003cp\u003ePeter A. McCullough (William Beaumont Hospital).\u003c\/p\u003e \u003cp\u003e16 Congestive heart failure: treatment implications of natriuretic.\u003c\/p\u003e \u003cp\u003epeptides.\u003c\/p\u003e \u003cp\u003eW Frank Peacock (Emergency Cardiology Research).\u003c\/p\u003e \u003cp\u003e17 Utilizing multimarker strategies in patients who present with.\u003c\/p\u003e \u003cp\u003econgestive heart failure.\u003c\/p\u003e \u003cp\u003eJohannes Mair (Universitaetsklinik fuer Innere Medizin).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Contemporary markers of risk\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e18 Clinical integration of C-reactive protein for primary and.\u003c\/p\u003e \u003cp\u003esecondary risk factor stratification.\u003c\/p\u003e \u003cp\u003eJesse E. Adams (Jewish Hospital Heart and Lung Institute).\u003c\/p\u003e \u003cp\u003e19 Lipoprotein subfraction analysis using nuclear magnetic.\u003c\/p\u003e \u003cp\u003eresonance spectroscopy.\u003c\/p\u003e \u003cp\u003eWilliam C. Cromwell (Presbyterian Center for Preventive Cardiology), Harold E. Bays (L-Marc Research Center), Peter P. Toth (Director of Preventive Cardiology).\u003c\/p\u003e \u003cp\u003eIndex\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49407872368983,"sku":"9781405134187","price":999.99,"currency_code":"GBP","in_stock":false}],"url":"https:\/\/bookcurl.com\/products\/markers-in-cardiology-9781405134187","provider":"Book Curl","version":"1.0","type":"link"}